

# Pharmacy BULLETIN BOARD

Retail Issue ■ Monday April 6, 2015

Odan Laboratories is pleased to introduce their new sodium chloride product:

## ODAN-SODIUM CHLORIDE

**OPHTHALMIC OINTMENT USP**

**Odan-Sodium Chloride™** ophthalmic ointment is indicated for the temporary relief of corneal edema

**The only equivalent to Muro-128<sup>†</sup>**

Product	Format	Odan	K & F	McKesson
<b>Odan-Sodium Chloride Ointment</b> NPN 80046696	3.5 g	12735	149285	067490
<b>Odan-Sodium Chloride Solution*</b> NPN 80046737	15 mL	12515	149153	067456

\*Covered by the British-Columbia formulary

To order, please contact your wholesaler or contact Odan directly by phone at 1-800-387-9342 or by e-mail at [info@odanlab.com](mailto:info@odanlab.com).



\*Odan Laboratories Ltd., Montreal, QC, Canada H9R 2Y6  
<sup>†</sup>Muro 128 is a registered trademark of Bausch & Lomb

### ■ FROM THE NEWSWIRE ■

**KIRKLAND, QC:** Merck, known as MSD outside the United States and Canada, has announced that GARDASIL<sup>®9</sup> (Human Papillomavirus 9-valent Vaccine, Recombinant), Merck's 9-valent human papillomavirus (HPV) vaccine, is now available in Canada. GARDASIL<sup>®9</sup> is indicated for use in girls and women 9 to 45 years of age for the prevention of cervical, vulvar, vaginal, and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58, pre-cancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, and genital warts caused by HPV types 6 and 11. GARDASIL<sup>®9</sup> is also approved for use in boys and men 9 to 26 years of age for the prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, 52 and 58, precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, and genital warts caused by HPV types 6 and 11. GARDASIL<sup>®9</sup> is contraindicated in individuals with hypersensitivity, including after a previous dose of GARDASIL<sup>®9</sup> or GARDASIL<sup>®</sup> [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine].

**OTTAWA:** Canada's Research-Based Pharmaceutical Companies (Rx&D) acknowledges the Patented Medicines Prices Review Board's (PMPRB) newly released report on Cost Drivers of Public Drug Plans in Canada. Rx&D notes that, according to the report, the rates of change in drug costs have been steadily declining in recent years, reaching a low of -0.8 percent in 2012/13 for a number of select public drug plans. But Rx&D cautions that any study that examines the costs of medicines without considering their overall impact on the system and how they factor in comparison to other costs could lead to inaccurate perspectives or analyses.

**OTTAWA:** The Honourable Rona Ambrose, Minister of Health, and Canada's Chief Public Health Officer, Dr. Gregory Taylor, have welcomed the news of promising trial outcomes of Canada's VSV-EBOV Ebola vaccine. The results of several studies and trials bring the world closer to ending this global outbreak through the provision of a commercially available vaccine.